Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May 1;42(5):472-9.
Print 2013.

Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China

Affiliations

Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China

Weilan Wang et al. Iran J Public Health. .

Abstract

Background: To evaluate off-label and off-NCCN guidelines uses of antineoplastic drugs in a major Chinese hospital.

Methods: Totally 1122 patients were selected from July to December 2011. Then, the off-label and off-NCCN guidelines uses of antineoplastic drugs were analyzed.

Results: In 798 of 1122 patients (71.12%), drugs were used for off-label. In 317 of 1122 patients (28.25%), the drugs were prescribed for off-label and off-NCCN guidelines. 2591 medical orders for 1122 patients, 1051/2591 (40.56%) medical orders were off-label; 445/2591(17.17%) medical orders were off-label and off-NCCN guidelines. In 445 off-label and off-NCCN medical orders, 399 (89.66%) were unapproved indications, 38 (8.54%) were unapproved drug concentration and 12 (2.70%) were unapproved route of administration. Percentage of off-label and off-NCCN guidelines drug uses in male was higher than that in female (21.92% vs. 11.39%, P<0.01). Compared with other lines of treatment, percentage of off-label and off-NCCN guidelines drug uses in postoperative adjuvant was the smallest (P<0.01) and percentage in three or multi-line treatments was the highest (P<0.01). The pancreatic cancer possessed the highest percentage (38.74%) of off-label and off-NCCN guidelines drug uses among all types of cancer (P<0.01).

Conclusion: Off-label uses of antineoplastic drugs are generally common in China hospitals based on NCCN guidelines. The fact suggests that anti-tumor treatment was relatively standard in China. Off-label and off-NCCN guidelines drug uses were mainly for individual treatment. Doctors should fully consider the adverse drug reaction, contraindication, cautions and increase the drug security monitoring. Uncorrected drug concentration should be avoided for drug risk.

Keywords: Antineoplastic drug use; China; Off-label and off-NCCN guidelines.

PubMed Disclaimer

Similar articles

Cited by

References

    1. American Academy of Pediatrics Uses of drugs not described in the package insert (off-label uses) Pediatrics. 2002;110(1):181–183. - PubMed
    1. American Society of Clinical Oncology Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol. 2006;24(19):3206–3208. - PubMed
    1. Soares M. “Off-label” indications for oncology drug use and drug compendia: History and current status. J Oncol Pract. 2005;1(3):102. - PMC - PubMed
    1. Conroy S, Newman C, Gudka S. Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol. 2003;14(1):42–47. - PubMed
    1. Leveque D, Michallat AC, Schaller C, Ranc M. Off label drug use in adult patients treated by anticancer chemotherapy. Bulletin du cancer. 2005;92(5):498–500. - PubMed

LinkOut - more resources